Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Nivalenol (NIV) was a mycotoxin that frequently contaminates wheat and causes vomiting and diarrhea. Oximmed NIV was bound to cationized bovine serum albumin. Mice were immunized with this conjugate. Cell fusion of the spleen cells from this mouse was performed. After HAT selection, anti-NIV antibody-producing cells were selected and cloned two or more times. We obtained 19 clones (NIV.1-19) of stable NIV-specific mAb-producing cells. For the first time, we succeeded in producing a mAb specific to NIV. Among these antibodies, competitive ELISA using NIV.9 or 10 antibody can detect NIV of 1 ng/mL or more. The development of a simple and highly sensitive method for measuring NIV is expected.
|